Calpastatin is the natural specific inhibitor of calpain. Recent research has linked uncontrolled calpain activation to tissue damage after neuronal and cardiac ischemias, traumatic spine and brain injuries, as well as Alzheimer's disease and cataract formation. An imbalance between the activities of calpain and calpastatin is believed to be responsible for the pathological role of calpain. An important key to understanding calpain regulation by calpastatin is to determine, at the molecular level, how calpastatin interacts with calpain to inhibit its enzymatic activity. A 27-residue peptide (DPMSS-TYIEELGKREVTIPPKYRELLA) derived from subdomain 1B of the repetitive domains of calpain, named peptide B27-WT, was previously shown to be a potent inhibitor of -and m-calpain. In this report, a combination of ␤-alanine scanning mutagenesis and kinetic measurements was used to probe, in a quantitative, systematic, and simultaneous fashion, the relative contribution of the amino acid side chain and backbone functionalities to the overall calpain-inhibitory activity of B27-WT. The study identified two "hot spots, backbones is required for the peptide inhibitory function. These results suggest a plausible model in which the two hot spots are situated at or near the interface(s) of the calpain-calpastatin complex and act in a concerted fashion to inhibit calpain. The information on the specific contribution of the amide bond and side chain of each key residue to the bioactivity of B27-WT will contribute to a better understanding of the mechanism of calpain inhibition and lead to novel and effective therapies based on the specific inhibition of dysregulated or overactivated calpain.
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Calpain (EC 3.4.22.17), a nonlysosomal, intracellular calcium-activated neutral cysteine proteinase, has been implicated in a variety of important physiological processes, including signal transduction, cell proliferation and differentiation, and apoptosis (1) (2) (3) (4) . The consequences of uncontrolled calpain activation have been witnessed in certain pathological conditions associated with excessive increases in intracellular Ca 2ϩ levels, namely, in tissue destruction after spine and brain injuries, neuronal injury after cardiac and brain ischemia, demyelination diseases (multiple sclerosis), muscular dystrophy, Alzheimer's disease, arthritis, and cataract formation (5, 6) . There are two well established calpain isoforms, -and m-calpain, 1 which are ubiquitously expressed and require micro-and millimolar concentrations of Ca 2ϩ to reach maximal activity, respectively, in vitro. The classical -and m-calpains exist as heterodimers consisting of a large (80-kDa) catalytic subunit and a small (28-kDa) regulatory subunit that dissociates in the presence of calcium (7) (8) (9) . Tissue-specific calpains and other calpain-related genes have now been identified (10) .
The activity of calpain is tightly regulated through Ca 2ϩ -induced conformational changes in the proteinase and by interaction with its specific endogenous inhibitor calpastatin (11) (12) (13) . Modulation of calpain activity by phospholipids and protein activators has also been reported (14) . Calpain and calpastatin are widely distributed in all animal cells, with calpastatin in excess of calpain in erythrocytes and heart muscle (1, 14) . It has recently been reported that calpastatin resides predominantly in phosphorylated-aggregated bodies, with the inhibitor protein being dephosphorylated and distributed in a Ca 2ϩ -dependent manner (11, 12) . This observation demonstrates the vigorous regulation placed on the calpaincalpastatin system whereby both enzyme and inhibitor are under strict Ca 2ϩ control. The primary structure of calpastatin is divided into four repeating inhibitory domains (domains [1] [2] [3] [4] and an NH 2 -terminal domain that lacks inhibitory function (domain L) (6, 15-19; see Fig. 1 ). The function of domain L is not clear, although it has been suggested that this domain may play a role in regulating calcium ion channels (16) . Inside each repetitive domain are three conserved subdomains referred to as A, B, and C. Subdomains A and C are rich in acidic residues that are scattered among hydrophobic residues and are predicted to form amphiphilic ␣-helices. It has been established, using the BIAcore surface plasmon resonance technology, that subdomain A binds to domain IV of the catalytic subunit of calpain, 1 The abbreviations and trivial names used are: -and m-calpain, the micromolar and millimolar Ca 2ϩ -requiring Ca 2ϩ -dependent proteinase, respectively; AMC, aminomethylcoumarin; DIPEA, N,NЈ-diisopropylethylamine; Fmoc, N-(9-fluorenyl)methoxycarbonyl; FTC, fluorescein thiocarbamoyl; HBTU, O-benzotriazole-1-yl-N,N,NЈ,NЈ-tetramethyluronium hexafluorophosphate; HPLC, high performance liquid chromatography; MALDI, matrix-assisted laser desorption ionization; Pbf, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl.
whereas subdomain C binds to domain VI in the regulatory subunit (17) (18) (19) . Although neither subdomain A nor C inhibits calpain activity directly, these subdomains do act to potentiate the inhibitory ability of calpastatin by promoting its tight binding to calpain (14, (17) (18) (19) . Previous studies using bacterially expressed calpastatin fragments have established that the inhibitory activity of calpastatin resides in subdomain B of the repeating structures (domains 1-4) (15, 20 -23) . Moreover, a chemically synthesized 27-residue peptide corresponding to subdomain 1B of human calpastatin showed strong inhibition against -and m-calpain, although to a slightly lesser extent than a whole functional domain 1 of calpastatin (18) . The subdomain 1B peptide, which we have named peptide B27-WT (see Fig. 2A (21) . It has been proposed that these ␤-turns could play an important role in mediating the biological activity of the peptide.
An important key to understanding calpain function and regulation is to determine, at the molecular level, how calpastatin interacts with calpain to inhibit its enzymatic activity. Recent x-ray crystallographic studies on Ca 2ϩ -free -and mcalpain, as well as the Ca 2ϩ -bound protease core (domains I and II) of -calpain have provided very important insights into possible mechanisms by which calpain could be activated by Ca 2ϩ (9, 13, 24) . However, no crystal structures or molecular modeling data are available for the calpain-calpastatin complex. Even though calpastatin subdomain B or peptide B27-WT was shown to be responsible for calpain inhibition, no rigorous structure-function analysis has been performed to examine the individual contributions of each amino acid residue to the overall inhibitory activity. Because this type of study is absolutely critical to establish a detailed understanding of the mechanism employed by B27-WT to inhibit calpain, we embarked on a study that would identify the structural elements in the peptide which are important for calpain inhibition. This was accomplished by using "␤-alanine scanning" mutagenesis to determine the effect of site-specific amide bond and/or side chain modifications on the biological activity of B27-WT.
EXPERIMENTAL PROCEDURES
Materials-Porcine erythrocyte calpain I was purchased from Calbiochem. Suc-Leu-Tyr-AMC was obtained from Sigma. Fmoc-protected amino acids, Fmoc-Ala-Wang resin, piperidine, DIPEA, HBTU, and trifluoroacetic acid were purchased from Advanced ChemTech (Louisville, KY). Dimethylformamide and tetrahydrofuran were purchased from Burdick & Jackson (Muskegon, MI) and used without further purification. All other reagents were of analytical grade.
Peptide Synthesis-The 27-residue calpastatin-(162-188)-peptide (B27-WT, DPMSSTYIEELGKREVTIPPKYRELLA) encoded by exon 1B of the human calpastatin gene (25) and its ␤-Ala-containing analogs (B27-␤-Ala-X) were synthesized using a multiple peptide synthesizer (Advanced ChemTech, model 348⍀) using Fmoc/t-butyl chemistry. All peptides were synthesized on 150 mg (0.12 mmol) of preloaded FmocAla-Wang resin (0.8 mmol/g; 100 -200 mesh). N-␣-Fmoc deprotection was performed with 25% piperidine in dimethylformamide followed by washing with tetrahydrofuran (4 ϫ 3 ml) and dimethylformamide (2 ϫ 3 ml). The Fmoc-amino acids were activated with 0.9 eq of HBTU and 2 eq of DIPEA and coupled for 45 min using a 5-fold excess of activated amino acids. Side chain protecting groups used were (t-butyl) for Asp, Glu, Ser, Thr, and Tyr; (Pbf) for Arg; (t-butoxycarbonyl) for Lys. Side chain deprotection and cleavage of peptides from the resin were performed with 3 ml of trifluoroacetic acid in the presence of phenol/ ethanedithiol/thioanisole/water (82.5:5:5:2.5:5, v/v). The crude peptides were purified by reverse phase HPLC on a Vydac C 18 column (10 m, 250 ϫ 50 mm; Grace Vydac, Hisperia, CA) using a linear gradient of 0.1% trifluoroacetic acid in water (buffer A) to 0.1% trifluoroacetic acid in acetonitrile (buffer B) over 100 min. Analytical reverse phase HPLC was performed on a Jupiter C 5 (10 m, 250 ϫ 4.6 mm; Phenomenex, Torrance, CA) using a 60-min gradient or a Discovery series C 18 (5 m, 150 ϫ 4.6 mm; Supelco, Inc., Bellefonte, PA) using a 40-min gradient of 100% buffer A to 100% buffer B. Beckman System Gold equipment (Beckman-Coulter, Fullerton, CA) was used for preparative HPLC, and analytical HPLC was performed with a Waters model 600E apparatus (Waters, Inc., Milford, MA). The purity of the peptides was confirmed by electrospray ionization and/or matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. The concentrations of the peptide solutions used for the calpain inhibition studies were determined by amino acid analysis performed at the University of Michigan Protein Structure Facility (Ann Arbor, MI).
Stopped-flow Measurements of Calpain Inhibition by Calpastatin Peptide B27-WT-Calpain activity was monitored using two different types of substrates: Suc-Leu-Tyr-AMC and fluorescein thiocarbamoylcasein (FTC-casein). The AMC fluorophore moiety of Suc-Leu-Tyr-AMC has negligible fluorescence when its amino group is involved in an amide bond with the peptidyl portion (Suc-Leu-Tyr) of the substrate. Upon cleavage of the Tyr-AMC amide bond by calpain, the released AMC product, with a free amino functionality, emits a strong fluorescence signal at 460 nm when excited at 370 nm. Fluorescence emitted by the fluorescein groups on FTC-casein (ϳ 3:1, number of probes/ molecule of casein) is quenched through fluorescence resonance energy transfer because of the close proximity of the probes (10 -100Å) on the intact substrate. An increase in fluorescence intensity is detected when FTC-casein is digested by calpain to produce fluorescein-labeled polypeptides that are distant from each other in solution.
Rapid kinetic measurements of calpain inhibition by B27-WT in the presence of either Suc-Leu-Tyr-AMC or FTC-casein were performed by stopped-flow fluorometry on an SX.18MV Stopped-Flow Reaction Analyzer (Applied Photophysics Ltd., Surrey, UK). The stopped-flow experiments were carried out under pseudo-first order conditions with B27-WT in at least 5-fold excess over calpain. Buffer conditions were as follows. Buffer C contained 20 mM HEPES, 130 mM KCl, 5 mM dithiothreitol, and 0.1 mM EDTA, pH 7.4. Buffer D contained 20 mM HEPES, 130 mM KCl, 5 mM dithiothreitol, and 2 mM CaCl 2 , pH 7.4. Two separate experiments were carried out to determine the dependence of the pseudo-first order rate constant, k obs , on inhibitor concentration using either Suc-Leu-Tyr-AMC or FTC-casein. A third experiment examined the dependence of k obs on Suc-Leu-Tyr-AMC concentration.
In the first set of experiments, the rate of calpain-mediated hydrolysis of Suc-Leu-Tyr-AMC was monitored at various concentrations of inhibitor. Excitation was at 370 nm, and a filter with a cutoff below 405 nm was used to monitor the emission of liberated AMC. Calpain was prepared at twice the final reaction concentration (50 nM) in buffer C, and twice the final reaction concentration of Suc-Leu-Tyr-AMC (0.2 mM) was prepared in buffer D. Various concentrations of inhibitor were premixed with substrate in buffer D to achieve final inhibitor concentrations between 0.1 and 1.1 M.
A second set of experiments was carried out in which FTC-casein was used as substrate to determine the dependence of k obs on inhibitor concentration. Fluorescein was excited at 490 nm, and a filter with a cutoff below 505 nm was used to observe fluorescence emission. 20 nM calpain and 1.0 M FTC-casein in buffer C (syringe 1) were rapidly reacted with 1.0 M FTC-casein and various concentrations of B27-WT in buffer D (syringe 2) to final concentrations of 10 nM calpain, 1 M FTC-casein, and peptide B27-WT (0.05-2.5 M). The final concentration of substrate (1.0 M) was prepared in both buffer C and D to prevent any change in fluorescence resonance energy transfer caused by dilution in the reaction cell.
For the third set of experiments, 1 M B27-WT and 50 nM calpain concentrations were fixed, and the concentration of Suc-Leu-Tyr-AMC was varied between 0.05 and 1.0 mM in the final reaction mixture. The filter settings were the same as in the first set of experiments.
Analysis of Stopped-flow Kinetic Data-The second order rate constant, k a , of B27-WT--calpain complex formation was determined under pseudo-first order conditions as described previously and could be best fit to Equation 1 (26) ,
where [P] is the product concentration, and v 0 and v s are the initial and steady-state velocities, respectively. k obs is the pseudo-first order rate constant for the approach to steady state and is described by Equation 2 (26) .
The Michaelis constants (K m ) for calpain-catalyzed hydrolysis of Suc-Leu-Tyr-AMC (3.29 Ϯ 0.18 mM) and FTC-casein (13.12 Ϯ 5.55 M) were determined experimentally using standard Lineweaver-Burk plots with substrate concentrations of 0.1-4 mM and 0.5-8 M for Suc-Leu-Tyr-AMC and FTC-casein, respectively (data not shown). All stopped-flow traces were best fit by a single exponential function with a linear component to obtain k obs and are reported as the averages of 6 -10 replicate traces. The functional inhibitor concentration was determined by dividing experimental inhibitor concentration by the factor 1 ϩ [S 0 ]/K m to correct for the competitive effect of the substrate. The second order association rate constant (k a ) was calculated from the slope of the linear regression fit to the dependence of k obs on the corrected inhibitor concentration, and the ordinate intercept gave the first order dissociation rate constant (k d ). For the substrate dependence reaction, k a was calculated from the slope of the linear regression fit to the dependence of k obs on 1/(1 ϩ [S o ]/K m ) divided by the concentration of B27-WT (1.0 M), and the ordinate intercept gave
Steady-state Kinetics of Calpain Inhibition by ␤-Ala-containing Analogs of B27-WT-The effects of single amino acid modifications on the calpain-inhibitory activity of the library of ␤-Ala-containing B27-WT analogs were evaluated using steady-state fluorescence measurements. Various concentrations of the inhibitor peptides in 20 l of assay buffer (20 mM HEPES buffer, pH 7.4, containing 130 mM KCl) and 0.76 g of calpain in 10 l of assay buffer were added to microtiter wells. After the solutions were mixed for 5 min, 65 l of assay buffer containing 1.5 mM CaCl 2 and 5 mM dithiothreitol was added, yielding a final concentration of 1.0 mM Ca 2ϩ , 0.05 mg/ml calpain, and 3.4 mM dithiothreitol. The enzyme-inhibitor complex was allowed to form while shaking the reaction mixture in the microtiter plate over a 15-min period, at which time 5.0 l of a 6 mM Suc-Leu-Tyr-AMC solution was added to reach a final substrate concentration of 300 M. Residual calpain activity in the enzyme-inhibitor complex was determined by measuring the fluorescence increase over time resulting from the Ca 2ϩ -dependent hydrolysis of Suc-Leu-Tyr-AMC, using a Fluoroscan Ascent FL microtiter plate reader (Labsystems, Inc.). The percent enzyme inhibition was determined by comparing the activity of the inhibitor-treated enzyme with that of a control reaction without inhibitor. The residual activities reported are the average of six to eight individual reactions for each inhibitor concentration tested. IC 50 values (inhibitor concentration required for half-maximal inhibitory activity) were determined after doseresponse curve analysis. Data were analyzed with the Ascent software version 2.4.1 provided with the instrument and a SigmaPlot 2001 software package (SPSS, Inc., Chicago).
Gel Electrophoresis-The Ca 2ϩ /calpastatin peptide-treated calpain samples were also analyzed by gel electrophoresis. 2 M calpain was incubated with various concentrations of B27-WT or 50 M B27-␤-Ala-X mutant in the presence or absence of Ca 2ϩ for 15 min. The reactions were terminated by adding equal volumes of 2 ϫ sample buffer (150 mM Tris-HCl, 20% glycerol, 4% w/v SDS, 10% v/v ␤-mercaptoethanol, and 0.04% bromphenol blue, pH 6.8), followed by heating the samples at 95°C for 5 min. Samples were stored at Ϫ20°C until ready to be analyzed. SDS-PAGE was performed using the buffer system described by Laemmli (27) . Gels were stained with GelCode ® Blue Stain Reagent (Pierce), and band intensities were analyzed by densitometry (Bio-Rad GelDoc model 2000).
RESULTS
Synthesis and Characterization of the Calpastatin Peptides-A 27-residue human calpastatin subdomain 1B (162-188) peptide (named B27-WT, DPMSSTYIEELGKREVTIPP-KYRELLA) was selected for this study. B27-WT and a library of B27-WT analogs containing specific positional modifications, a ␤-Ala substitution (␤-alanine scan), as shown in Fig. 2A , were synthesized. A group of NH 2 -terminally truncated fragments of B27-WT was also generated (Fig. 2B) . The synthetic peptides were purified to near homogeneity by HPLC, and their molecular weights were confirmed by electrospray ionization and/or MALDI mass spectrometry (Table I) . No contamination by modified or incompletely deprotected peptides was detected after final purification.
Calpain Inhibition by Calpastatin Peptide B27-WTStopped-flow kinetic measurements were used to investigate the effectiveness and the mechanism of calpain inhibition by B27-WT. A simple, competitive inhibition was assumed, as shown in Scheme I,
where k a is the second order rate constant of complex formation and k d is the rate constant of its decomposition. Stopped-flow traces of the fluorescence changes observed after rapid mixing of calpain with various concentrations of inhibitor preincubated with fixed concentrations of fluorogenic peptide (200 M) or fluorescently labeled casein (1 M) substrate are shown in Fig. 3, A and B , respectively. The dependence of the pseudo-first order rate constant (k obs ) on the concentration of B27-WT was also examined. The experiments were performed under pseudo-first order conditions ([B27-WT] Ͼ Ͼ [calpain I]), which were verified by the independence of k obs on the concentration of calpain. The combination of a decrease in the steady-state rate, i.e. inhibition (Fig. 3, A and B) and an increase in k obs as the concentration of B27-WT increases (Fig.  4, A and B) provides evidence for a competitive component to the inhibitory mechanism. As shown in Fig. 4 , k obs increased linearly with increasing concentrations of B27-WT up to the highest concentration investigated, when either Suc-Leu-Tyr-AMC (Fig. 4A) or FTC-casein (Fig. 4B ) was used as substrate, confirming a classical competitive inhibition in both cases. For the experiments performed with Suc-Leu-Tyr-AMC, a second order association rate constant (k a ) of (8.14 Ϯ 0.21) ϫ 10 The nomenclature for the library is specified on the right of the figure. The mutant peptides are numbered ␤-Ala 1 -␤-Ala 27 starting at the NH 2 terminus. The peptide with no structural modification was named B27-WT and, for example, the peptide with Pro 19 replaced by ␤-Ala was named B27-␤-Ala 19 . B, NH 2 -terminally truncated fragments of B27-WT. Truncated peptides were generated starting with an 11-mer (CLP-1) that contains only the type I ␤-turn. The residues linking the type I and type II ␤-turns were added two at a time (CLP-2 and -3) until Gly-12 (CLP-4). Ϫ1 obtained from the substrate dependence studies were in good agreement with those determined from the inhibitor dependence studies. The rapid kinetic measurements demonstrate that B27-WT exhibits a tight, reversible, and competitive inhibition of calpain in the presence of either a protein (casein) or a small molecular weight (Suc-Leu-Tyr-AMC) substrate.
TABLE I Analysis of the synthetic peptides for purity and for calpain inhibitory activity
Evaluation of the Contribution of Individual Amino Acid Residues to the Overall Bioactivity of B27-WT-To determine the individual contribution of each residue in B27-WT to the overall inhibitory function, we measured the effect of the native peptide and its ␤-Ala mutants ( Fig. 2A) on porcine erythrocyte calpain activity. The IC 50 values for B27-WT and the mutant peptides are tabulated in Table I , and the dose-response curves of calpain inhibition by peptides mutated in the hot spots and putative ␤-turn regions are shown in Fig. 5 .
The inhibitory activities of the ␤-Ala mutant peptides have been grouped into four main categories: strong (IC 50 Ͻ 50 nM), moderate (IC 50 ϭ 50 -100 nM), weak (IC 50 ϭ 100 -300 nM), or no inhibition against calpain (IC 50 Ͼ 750 nM). As shown in Table  I with ␤-Ala had a moderate effect (IC 50 ϭ 50 -85 nM) on the inhibitory potential of the peptide. B27-␤-Ala mutations at positions 1, 7, 9, 13, 16, 20, and 22 were weak inhibitors (IC 50 ϭ 100 -130 nM). Mutants B27-␤-Ala 10 and Ala 14 showed very weak inhibitory activities (IC 50 ϭ 180 -280 nM), whereas a group of mutants comprising B27-␤-Ala at positions 11, 12, 17, 18, and 19 exhibited practically no inhibition (IC 50 Ͼ 750 nM) against calpain (see Fig. 5, A and B regions play a critical role in mediating the inhibitory activity of the peptide. Furthermore, B27-␤-Ala 12 (IC 50 Ͼ 750 nM), in which a -CH 2 -group was inserted between the N␣ and C␣ of Gly 12 , exhibited more than a 15-fold decrease in inhibitory activity relative to the native peptide, B27-WT (IC 50 ϭ 33 nM). However, replacing Lys 13 with ␤-Ala produced a relatively small effect (IC 50 ϭ 99 nM) on the potency of the peptide. Because the Gly residue has no side chain, this ␤-Ala-based mutagenesis study clearly revealed the importance of the Gly 12 -Lys 13 amide bond for the overall inhibitory effect of peptide B27 on calpain. To probe the contribution of the Leu 11 -Gly 12 amide bond, we carried out a classical "L-Ala substitution" which conserved the amide bond but modified the side chain functionality of Leu 11 . The Leu 11 3 Ala 11 mutant was found to exhibit an IC 50 of 113 nM (Fig. 5A) (see Table I and Fig. 5C ). As can be deduced easily from a comparison of the IC 50 values of 33, Ͼ300, and Ͼ1,000 nM for B27-WT, B27-Ala 18 , and B27-␤-Ala 18 , respectively, both the Ile 18 -Pro 19 backbone and the side chain of Ile 18 contribute to the B27-WT bioactivity. Thus, in addition to participating with its carbonyl group to the bioactive conformation of B27-WT, Ile 18 also provides a hydrophobic side chain that appears to be a key structural element for the inhibitory function of peptide B27. This finding suggests that the Ile 18 side chain is potentially involved in protein-protein interaction with calpain.
The other key residues in B27-WT are Thr 17 and Pro 19 . Replacement of either Thr 17 or Pro 19 with ␤-Ala resulted in a significant loss of inhibitory function (Fig. 5B) (Fig. 5C , IC 50 ϭ 44 nM), with a typical amide bond instead of the imide bond between Ile 18 and Pro 19 in the native peptide, exhibited close to a full inhibitory activity compared with the native peptide B27-WT (IC 50 ϭ 33 nM) and the noninhibitory B27-␤-Ala 19 mutant (Fig. 5B) . Therefore, even though Pro 19 is a highly conserved residue across three different species (pig, rabbit, and human) and repetitive domains (domains 1-4) of calpastatin, a Pro residue does not seem to be absolutely required in position 19 to maintain the calpaininhibitory function of the inhibitor. However, a normal peptide bond between the 19th and 20th residues is necessary to retain the bioactive conformation of B27-WT.
Two regions in calpastatin subdomain 1B, Glu 10 19 ) to the ␤-turns. Taken together, our structure-activity analysis has identified important contributions of the amide backbones as well as the side chains of some key amino acid residues, clustered at two hot spots, Leu 11 -Gly 12 and Thr 17 -Ile 18 -Pro 19 , within B27-WT which are absolutely critical for the overall activity of the inhibitor. Furthermore, the results of this study demonstrate that the simultaneous or concerted interaction of the two hot spots is required for inhibitory activity because mutation of either one of these key residues resulted in the complete loss of activity. This observation is supported further by the fact that NH 2 -terminally truncated fragments of B27-WT (Fig. 2B ) lacking any one of these key residues failed to inhibit calpain.
Effect of B27-WT and Its ␤-Ala Mutants on Calpain Autolysis-The activation of calpain involves more than a simple Ca 2ϩ -induced conformational change. On incubation with Ca 2ϩ , the NH 2 termini of the catalytic and regulatory subunits of the enzyme are rapidly autolyzed from 80 to 76 kDa, and 28 to 18 kDa, respectively (28) . Careful examination of bovine erythrocyte calpain I autolysis in vitro, under conditions that slowed down the process, revealed a two-stage limited cleavage of a 14-amino acid segment from the NH 2 terminus of the catalytic subunit to yield a 78-kDa intermediate form, followed by cleavage of an additional 12-amino acid segment to yield the 76-kDa active enzyme form. Cleavage of the 28-kDa subunit was subsequent to generation of the 76-kDa catalytic form (28) . Because autolysis of the classical -and m-calpains appears to be an intermolecular event that could be inhibited by a calpain inhibitor, we decided to examine the ability of B27-WT to block the autoproteolytic processing of the catalytic subunit of porcine erythrocyte -calpain. The native 80-kDa subunit was converted to a 76-kDa form within 1 min when 2 M calpain was incubated with 1 mM Ca 2ϩ in the absence of inhibitor (Fig.  6, Ϫcontrol) . It must be noted here that the commercial preparation of the enzyme, which we used for the autolysis experiment, contained both the 80-and 76-kDa forms of the catalytic subunit (Fig. 6, ϩcontrol) . When calpain was incubated with calcium and B27-WT at inhibitor concentrations that did not completely inactivate the enzyme, the 78-kDa intermediate form of the catalytic subunit was "trapped" during the autoproteolytic process. The extent of autolytic conversion of the intact large subunit from an 80-kDa protein to 78-and 76-kDa fragments depended on the concentration of inhibitor in the preincubation mixture (Fig. 6) . Above 110 M inhibitor, only the intact 80-and the contaminant 76-kDa bands could be seen, whereas at inhibitor concentrations between 10 and 100 M, the 78-kDa form was also present. Considering the fact that the original enzyme preparation contained some of the 76-kDa form as a contaminant (Fig. 6, ϩcontrol) , it appears that a 50-fold molar excess of B27-WT effectively inhibited the initial stage (80 to 78 kDa) of autolysis.
We next examined the contribution of each amino acid residue in B27-WT to the overall effectiveness of the peptide in blocking autolysis. 2 M -calpain was preincubated with a 25-fold molar excess of B27-WT or one of the 27 ␤-Ala mutants in the presence of 1 mM Ca 2ϩ for 15 min, followed by SDS-PAGE of the reaction mixture. At this inhibitor concentration (50 M), B27-WT slowed the two-step conversion of the 80-kDa subunit to the 76-kDa form, generating a mixture of 80-, 78-, and 76-kDa forms (Fig. 7, WT lane) .
With the exception of two mutants, B27-␤-Ala 6 (IC 50 ϭ 59 nM) and B27-␤-Ala 8 (IC 50 ϭ 64 nM), which were not as effective in inhibiting autolysis as suggested by their IC 50 values, the B27-␤-Ala-X mutants with moderate to strong inhibitory activities (IC 50 Յ 100 nM) slowed both steps of autolysis (80 to 78 kDa and 78 to 76 kDa) with an efficacy comparable with what was obtained with 50 M B27-WT. On the other hand, 50 M B27-␤-Ala 20 (IC 50 ϭ 129 nM) inhibited both autolytic steps. The IC 50 values for B27-␤-Ala at positions 6, 8, and 20 are close to the borderline (100 nM) between the moderate and weak categories of inhibitors. Thus, the apparent discrepancies between the qualitative autolysis data and quantitative substrate kinetic results for these three mutants seem to be within an allowable margin of experimental error. As a general trend, B27-␤-Ala-X mutants that were weakly effective (IC 50 ϭ 100 -300 nM) in inhibiting the Suc-Leu-Tyr-AMC hydrolytic activity of porcine -calpain (see Table I ) blocked only the second step (78 to 76 kDa) of the autolytic process, resulting in the accumulation of the 78-kDa form of the catalytic subunit and a loss of the 80-kDa subunit in the presence of Ca 2ϩ . Mutants that exhibited practically no inhibitory activities (IC 50 Ͼ 1000 nM) against the substrate cleaving ability of calpain were unable to inhibit any of the early steps of autolysis (Fig. 7) . This study suggests that in the presence of nonphysiological levels of Ca 2ϩ , the calpastatin peptide could inhibit the ability of calpain to proteolyze its substrates by blocking the formation of the 76-kDa form of the catalytic subunit.
DISCUSSION
Peptide deletion/truncation experiments have been used previously to localize the inhibitory activity of calpastatin to re- gions around a well conserved sequence, TIPPXYR, in subdomain B of each of the four repeating domains of the protein (15, 23) . Despite its usefulness in determining the minimum active sequence necessary for bioactivity, the peptide truncation approach provides few details about the contributions of each residue to the overall biological function of a protein. Classical L-amino acid residue replacement approaches, such as alanine scanning, made possible using the tools of molecular biology, allow systematic structural modifications at the resolution of individual residues and are good for monitoring side chain interactions. However, these point mutations do little to probe the conformational properties of the peptide backbone. Furthermore, alanine, proline, glycine and cysteine ("nonentropic" amino acids) are not usually mutated in alanine scans (29) . The work presented in this report combined ␤-alanine scanning mutagenesis with kinetic measurements to probe, in a quantitative, systematic, and simultaneous fashion, the relative contribution of each amino acid side chain and peptide backbone (main chain) in the functional region of calpastatin to the overall calpain-inhibitory activity. The ␤-alanine substitution modifies both the amino acid side chain and the COOHterminal amide bond of the residue being probed. This strategy enables "structure-conformation-activity relations" (SCARs) to be delineated if further analyses are carried out on key residues to differentiate an effect because of a side chain modification from one that is the result of a change in peptide (amide) bond conformation. The SCARs approach is, therefore, capable of providing insights into the importance of different side chain groups and/or specific amide bonds for ligand-receptor interactions, which normal L-Ala scanning cannot provide.
Earlier studies by Cottin et al. (30) and by Shiba et al. (31) on the mechanism of calpain inhibition by calpastatin indicated a noncompetitive type of inhibition. However, more recent studies, performed in two independent laboratories, on calpain inhibition by calpastatin-derived peptides showed a competitive type of inhibition (15, 23) . Graphical methods (Dixon plots) were used to examine the kinetics of inhibition in all of the above mentioned studies. As pointed out by Laskowski and Sealock (32) , graphical methods are not suitable for the determination of the mechanism of tight binding inhibitors. To circumvent the problems associated with the analyses of tight binding inhibition, calpastatin peptides that were derived from the most weakly inhibiting domain of the four repetitive domains of calpastatin were used in the more recent studies (15, 23) .
In the first part of our study, stopped-flow kinetic measurements were used to determine the k a , k d , and K i values and the mechanism of inhibition of calpain by B27-WT, derived from the most potent inhibitory subdomain of calpastatin. A competitive type of inhibition was observed when either FTC-casein or a small molecular weight dipeptide fluorogenic substrate (SucLeu-Tyr-AMC) was used for the assay. Our results suggest that B27-WT competes with either of the substrates for interaction with calpain. The binding of B27-WT to calpain is not expected, however, to proceed through direct interaction with the catalytic center cysteine of the proteinase. B27-WT probably functions like an exosite binding inhibitor that interacts with surface residues adjacent to the active center of calpain, preventing access of substrates to the active center, without direct blockage of the catalytic residues. This mechanism is supported by the observation that calpain, with the active center cysteine protected with either a reversible or irreversible inhibitor, still retains the ability to efficiently bind a calpastatin subdomain B peptide (23, 33) . This experimental observation has been exploited in our laboratory to purify calpain from bovine kidney and heart (33) . Purification was accomplished by passing the active site inhibitor-treated crude tissue extract through a column charged with B27-WT immobilized on CNBr-activated Sepharose 4B (Amersham Biosciences). Further support is provided by a study described by Croall and McGrody in 1994 (34) , in which a cysteine-specific cross-linking of an inhibitory calpastatin peptide to calpain did not result in the labeling of the active site cysteine of the enzyme. The study also suggested that the binding site for the calpastatin peptide was close to domain III of the catalytic subunit of calpain.
The main goal of our study was to determine the structural elements in B27-WT that are critical for its biological activity. Previous studies have shown that the calpastatin polypeptide is largely a random coil in solution (22, 35, 36) . This earlier observation was supported further by evidence from 1 H NMR studies (21) and circular dichroism spectroscopy experiments performed by our group, 2 demonstrating the absence of regular secondary structures such as ␣-helix and ␤-sheets in B27-WT. Based upon these findings, we hypothesized that the specific and high affinity binding of B27-WT to calpain is most likely the result of multisite protein-peptide interactions mediated by small and discrete structural elements present in key residues in the peptide. Therefore, by modifying the side chain and/or peptide backbone of the key B27-WT residues, the ability of the peptide to inhibit calpain would be altered. Through ␤-Ala scanning and conventional Ala mutations on selected amino acids, we identified, for the first time, two hot spots, Leu 11 -Gly 12 and Thr 17 -Ile 18 -Pro 19 , in calpastatin subdomain 1B within which the key amide backbones as well as amino acid side chains that are most critical for the overall activity of the inhibitor are clustered. Mutation of any one of the key residues in either of the two hot spots resulted in a dramatic loss of inhibitory activity, suggesting that a simultaneous or concerted interaction involving both hot spots is required for inactivation of calpain by the calpastatin inhibitor peptide. Because hot spots tend to cluster near the center of protein-protein interfaces (29), we predict that the key contact residues of the calpain-calpastatin complex are located in this region of the peptide.
Of 26 amide bonds and 25 side chains that are present in B27-WT, we have been able to pinpoint the key structural elements that are crucial for the biological activity of the pep- the positional modifications introduced in the ␤-Ala library of the peptide perturbed the bioactive conformation and/or the fully productive interaction of the bioactive conformation(s) with calpain is not completely clear at this stage of our study. NMR studies have been scheduled to investigate whether B27-WT assumes an overall better structured conformation upon binding to calpain in the presence of calcium and whether mutation of a key residue could disrupt the overall structural integrity of the calpain-bound peptide. It must be noted, however, that even x-ray crystallography and NMR studies do not easily resolve the fundamental issue of distinguishing between direct effects of a substitution on inhibition and indirect effects caused by structural changes. Nevertheless, the present study integrated the functional importance of individual residues with the structural and dynamic aspects of inhibition. We propose a structural model for the competitive inhibition of calpain by B27-WT in which the two hot spots in the inhibitor interact with two separate sites in the extended substrate binding region of the proteinase in a manner akin to the closing of a "gate" leading to the active site of the enzyme. This model is being tested by using photoaffinity labeling techniques to map the topology of the inhibitor binding region.
The number of human diseases linked to uncontrolled calpain activation continues to increase (41) . The pathological role of calpain has been attributed to an imbalance between calpain and calpastatin activities, underscoring the importance of elucidating the structural basis of the inhibitory activity of calpastatin. Although the exact mechanism by which calpastatin inhibits calpain remains unclear, the present study has provided very useful insights into the possible mode of action of B27-WT by pinpointing the structural determinants of the biological activity of the inhibitor. It is expected that the information derived from this study will contribute an important part to the overall understanding of calpain inhibition and possibly lead to novel and effective therapies based on the specific inhibition of dysregulated or overactivated calpain.
